Daprodustat:Daprodustat for the Treatment of Anemia in Patients Not ...
Daprodustat for the Treatment of Anemia in Patients Not ...
由AKSingh著作·2021·被引用115次—Daprodustatisanoralhypoxia-induciblefactorprolylhydroxylaseinhibitor.Inpatientswithchronickidneydisease(CKD)whoarenot ...。其他文章還包含有:「Daprodustat」、「Daprodustat」、「Daprodustat」、「EffectsofDaprodustat」、「EfficacyandSafetyofDaprodustatforTreatmentofAnemia...」、「Jesduvroq(daprodustat)approvedbyUSFDAforanaemia...」、「Jesduvroq(daprodustat)核可適...
查看更多 離開網站Daprodustat
https://en.wikipedia.org
Daprodustat, sold under the brand name Duvroq among others, is a medication that is used for the treatment of anemia due to chronic kidney disease.
Daprodustat
https://pubmed.ncbi.nlm.nih.go
Daprodustat (DUVROQ) is a small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase (PHD) developed by GlaxoSmithKline for the treatment of ...
Daprodustat
https://www.ncbi.nlm.nih.gov
Daprodustat (DUVROQ) is a small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase (PHD) developed by GlaxoSmithKline for the ...
Effects of Daprodustat
https://pubmed.ncbi.nlm.nih.go
Background: Daprodustat (GSK1278863) is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor being developed for treatment of anemia associated with ...
Efficacy and Safety of Daprodustat for Treatment of Anemia ...
https://pubmed.ncbi.nlm.nih.go
Importance: Daprodustat, a hypoxia-inducible factor prolyl hydroxylase inhibitor, is being evaluated as an oral alternative to conventional ...
Jesduvroq (daprodustat) approved by US FDA for anaemia ...
https://www.gsk.com
Jesduvroq (daprodustat) approved by US FDA for anaemia of chronic kidney disease in adults on dialysis ... Jesduvroq is the first innovative ...
Jesduvroq (daprodustat)核可適用於慢性腎病引起之貧血 ...
https://www.taiwan-pharma.org.
Jesduvroq(daprodustat) 每日口服一次,飯前、飯後皆可,給藥起始劑量需依照患者紅血球程度、肝功能與其他治療等因素作調整,有五種劑量之錠劑:1 mg、2 mg、4 mg、6 mg ...
《FDA》核准葛蘭素(GSK)慢性腎臟病引起貧血口服新藥 ...
http://www.genetinfo.com
在日本,daprodustat 的品牌名稱是Duvroq,是市場領導者和首選HIF-PHI。 ASCEND III 期臨床試驗. 包括五項III 期試驗,以評估daprodustat 治療CKD 貧血的 ...
慢性腎病貧血藥進展,GSK 更新美國FDA 新藥審查進度
https://geneonline.news
Daprodustat 是一種新型口服缺氧誘導因子脯氨酰羥化酶抑製劑(hypoxia-inducible factor prolyl hydroxylase inhibitor, HIF-PHI) ,用於治療罹患CKD 非 ...